BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 16870237)

  • 41. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
    Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of brain metastases in patients with high-risk gestational trophoblastic tumors.
    Newlands ES; Holden L; Seckl MJ; McNeish I; Strickland S; Rustin GJ
    J Reprod Med; 2002 Jun; 47(6):465-71. PubMed ID: 12092015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recurrent gestational trophoblastic tumor: management and risk factors for recurrence.
    Yang J; Xiang Y; Wan X; Yang X
    Gynecol Oncol; 2006 Nov; 103(2):587-90. PubMed ID: 16750258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital.
    Cagayan MS; Lu-Lasala LR
    J Reprod Med; 2006 Oct; 51(10):785-92. PubMed ID: 17086807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
    Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
    Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of high-risk gestational trophoblastic disease.
    Lurain JR
    J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI
    Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
    Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
    Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
    Mao Y; Wan X; Lv W; Xie X
    Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of patients with trophoblastic tumors in the Academic Medical Center: 31 patients in 10 years, 1983-1992].
    Laan R; Bakker P; Lammes FB
    Ned Tijdschr Geneeskd; 1995 Sep; 139(36):1829-34. PubMed ID: 7477506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989.
    Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Holden L
    Br J Obstet Gynaecol; 1991 Jun; 98(6):550-7. PubMed ID: 1651757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy.
    Randall TC; Coukos G; Wheeler JE; Rubin SC
    Gynecol Oncol; 2000 Jan; 76(1):115-7. PubMed ID: 10620452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen.
    Kim SJ; Bae SN; Kim JH; Kim CJ; Jung JK
    Gynecol Oncol; 1998 Nov; 71(2):247-53. PubMed ID: 9826467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver metastases of gestational trophoblastic tumor.
    Bakri YN; Subhi J; Amer M; Ezzat A; Sinner W; Tweijry A; Jabbar FA
    Gynecol Oncol; 1993 Jan; 48(1):110-3. PubMed ID: 8380786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease.
    Soper JT; Evans AC; Rodriguez G; Berchuck A; Clarke-Pearson DL; Hammond CB
    Gynecol Oncol; 1995 Mar; 56(3):421-4. PubMed ID: 7705678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
    McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
    J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Methotrexate in gynecologic oncology].
    Isonishi S; Terashima Y
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1896-900. PubMed ID: 8978793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy.
    Lurain JR; Brewer JI
    Obstet Gynecol; 1985 Jun; 65(6):830-6. PubMed ID: 2987766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.